BR0212919A - Muteìnas da lipocalina associada à gelatinase de neutrófilos humanos e proteìnas relacionadas - Google Patents

Muteìnas da lipocalina associada à gelatinase de neutrófilos humanos e proteìnas relacionadas

Info

Publication number
BR0212919A
BR0212919A BR0212919-1A BR0212919A BR0212919A BR 0212919 A BR0212919 A BR 0212919A BR 0212919 A BR0212919 A BR 0212919A BR 0212919 A BR0212919 A BR 0212919A
Authority
BR
Brazil
Prior art keywords
human neutrophil
neutrophil gelatinase
associated lipocalin
protein
related proteins
Prior art date
Application number
BR0212919-1A
Other languages
English (en)
Other versions
BRPI0212919B1 (pt
BRPI0212919B8 (pt
Inventor
Arne Skerra
Steffen Schlehuber
Original Assignee
Pieris Proteolab Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Proteolab Ag filed Critical Pieris Proteolab Ag
Publication of BR0212919A publication Critical patent/BR0212919A/pt
Publication of BRPI0212919B1 publication Critical patent/BRPI0212919B1/pt
Publication of BRPI0212919B8 publication Critical patent/BRPI0212919B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

"MUTEìNAS DA LIPOCALINA ASSOCIADA à GELATINASE DE NEUTRóFILOS HUMANOS E PROTEìNAS RELACIONADAS". A presente invenção refere-se a um processo, que é descrito para gerar uma muteína de uma proteína selecionada do grupo que consiste da lipocalina associada à gelatinase de neutrófilos humanos (hNGAL), da proteína relacionada à <244>~ 2~-microglobulina de rato (A2m) e da 24p3/uterocalina (24p3) de camundongos, a dita muteína possuindo afinidade detectável a um certo alvo. O processo compreende a etapa de submeter a proteína à mutagênese em uma ou mais das posições de seq³ência que correspondem às posições de seq³ência 33 até 54, 66 até 83, 94 até 106 e 123 até 136 da hNGAL, resultando em uma ou mais muteínas da proteína. São também descritas as muteínas que podem ser obtidas através deste processo.
BRPI0212919A 2001-09-27 2002-09-18 "muteínas da lipocalina associada à gelatinase de neutrófilos humanos, proteínas relacionadas, composição farmacêutica, método para geração e uso das mesmas". BRPI0212919B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2001/011213 WO2003029462A1 (en) 2001-09-27 2001-09-27 Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
EP0204223 2002-04-16
PCT/EP2002/010490 WO2003029463A2 (en) 2001-09-27 2002-09-18 Muteins of human neutrophil gelatinase-associated lipocalin and related proteins

Publications (3)

Publication Number Publication Date
BR0212919A true BR0212919A (pt) 2004-10-13
BRPI0212919B1 BRPI0212919B1 (pt) 2017-05-30
BRPI0212919B8 BRPI0212919B8 (pt) 2021-05-25

Family

ID=38009239

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0212919A BRPI0212919B8 (pt) 2001-09-27 2002-09-18 "muteínas da lipocalina associada à gelatinase de neutrófilos humanos, proteínas relacionadas, composição farmacêutica, método para geração e uso das mesmas".

Country Status (12)

Country Link
US (1) US7252998B2 (pt)
EP (1) EP1430131B1 (pt)
JP (1) JP4396923B2 (pt)
CN (1) CN1325644C (pt)
AT (1) ATE311451T1 (pt)
AU (1) AU2002337111B2 (pt)
BR (1) BRPI0212919B8 (pt)
CA (1) CA2461571C (pt)
DE (1) DE60207740T2 (pt)
ES (1) ES2253561T3 (pt)
HK (1) HK1067145A1 (pt)
WO (2) WO2003029462A1 (pt)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
AU2003275958A1 (en) * 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US7776824B2 (en) 2004-05-06 2010-08-17 The Trustees Of Columbia University NGAL for reduction and amelioration of ischemic and nephrotoxic injuries
EP1814988A2 (en) 2004-11-26 2007-08-08 Pieris AG Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
DE602005013288D1 (de) * 2004-12-20 2010-05-06 Antibodyshop As M lipocalin (ngal) als diagnostischer marker für nierenerkrankungen
US7611847B2 (en) 2005-06-01 2009-11-03 Agency For Science, Technology And Research Method for identifying an intestinal phenotype
EP1989529A4 (en) 2006-02-13 2010-09-01 Agency Science Tech & Res PROCESS FOR PROCESSING A BIOLOGICAL AND / OR CHEMICAL SAMPLE
JP4987885B2 (ja) 2006-03-09 2012-07-25 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 小滴中で反応を行うための装置及びその使用方法
WO2007137584A1 (en) 2006-05-30 2007-12-06 Antibodyshop A/S Methods and devices for rapid assessment of severity of injury
AU2007280398B2 (en) 2006-08-01 2012-05-10 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
US20100210031A2 (en) * 2006-08-07 2010-08-19 Antibodyshop A/S Diagnostic Test to Exclude Significant Renal Injury
WO2008066752A2 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R & D Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
WO2010120249A1 (en) 2009-04-17 2010-10-21 Curiox Biosystems Pte Ltd Use of chemically patterned substrate for liquid handling, chemical and biological reactions
US9874501B2 (en) 2006-11-24 2018-01-23 Curiox Biosystems Pte Ltd. Use of chemically patterned substrate for liquid handling, chemical and biological reactions
WO2008063135A1 (en) 2006-11-24 2008-05-29 Agency For Science, Technology And Research Apparatus for processing a sample in a liquid droplet and method of using the same
CN101680903A (zh) 2007-03-21 2010-03-24 比奥波托诊断股份公司 肾损伤的诊断试验
JP2010523652A (ja) 2007-04-13 2010-07-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 腫瘍発生を制御する方法および腫瘍発生のリスクを診断する方法
US8454895B2 (en) 2007-05-03 2013-06-04 Nanyang Technological University Online contaminant detection and removal system
US8937153B2 (en) * 2007-07-31 2015-01-20 Affibody Ab Compositions, methods and uses
SG150405A1 (en) 2007-08-29 2009-03-30 Agency Science Tech & Res Method of coating a particle
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8846036B2 (en) * 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090269777A1 (en) * 2007-10-19 2009-10-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090123970A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Glycosylated mammalian ngal and use thereof
JP5746861B2 (ja) * 2007-10-19 2015-07-08 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 哺乳動物のｎｇａｌに結合する抗体及びその使用
US20090176274A1 (en) * 2007-10-19 2009-07-09 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US8969313B2 (en) 2007-11-02 2015-03-03 Agency For Science, Technology And Research Methods and compounds for preventing and treating a tumour
WO2013114217A1 (en) 2012-02-05 2013-08-08 Curiox Biosystems Pte Ltd. Array plates and methods for making and using same
US10725020B2 (en) 2007-11-14 2020-07-28 Curiox Biosystems Pte Ltd. High throughput miniaturized assay system and methods
CN101910845A (zh) * 2007-11-15 2010-12-08 比奥波托诊断股份公司 个体分子形式的生物标志的诊断用途
US20090274623A1 (en) * 2008-01-30 2009-11-05 General Electric Company In vivo imaging agents for met receptor tyrosine kinase
EP2283118A4 (en) 2008-05-06 2012-11-21 Agency Science Tech & Res METHOD FOR REALIZING THE DIFFERENTIATION OF A CELL
WO2009140599A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
WO2009142773A2 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
AU2013224694B2 (en) * 2008-06-24 2015-09-10 Technische Universitaet Muenchen MUTEINS OF hNGAL AND RELATED PROTEINS WITH AFFINITY FOR A GIVEN TARGET
JP5711118B2 (ja) * 2008-06-24 2015-04-30 テクニッシュ ウニヴェルジテート ミュンヘン 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
EP2321405A4 (en) 2008-08-08 2012-09-12 Agency Science Tech & Res MICROFLUIDIC CONTINUOUS FLOW DEVICE
US8716420B2 (en) 2008-10-13 2014-05-06 Agency For Science, Technology And Research Amphiphilic polymers and nanocrystals coated therewith
EP2189539B2 (en) 2008-11-21 2018-06-13 Chimera Biotec GmbH Conjugate complexes for analyte detection
US10464811B2 (en) 2009-04-06 2019-11-05 Nanyang Technological University Method of forming a particulate porous metal oxide or metalloid oxide
JP2012532607A (ja) 2009-07-07 2012-12-20 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 一対の結合パートナーを同定する方法
KR20120099371A (ko) 2009-08-05 2012-09-10 피어이스 에이지 리포칼린 뮤테인의 조절 방출 제형
SG10201408073XA (en) * 2009-12-07 2015-01-29 Pieris Ag Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
WO2011078794A1 (en) 2009-12-22 2011-06-30 Agency For Science, Technology And Research Sers-based analyte detection
RS56231B1 (sr) 2010-02-04 2017-11-30 Morphotek Inc Polipeptidi i konjugati hlorotoksina i njihove upotrebe
SG184345A1 (en) 2010-03-31 2012-11-29 Agency Science Tech & Res Amphiphilic linear peptide/peptoid and hydrogel comprising the same
EP3165533B1 (en) 2010-05-11 2020-04-08 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates and methods for their use
ES2667066T3 (es) 2010-05-24 2018-05-09 The Trustees Of Columbia University In The City Of New York Proteínas NGAL mutantes y usos de las mismas
WO2011154420A2 (en) 2010-06-08 2011-12-15 Pieris Ag Tear lipocalin muteins binding il-4 r alpha
US9878328B2 (en) 2010-07-23 2018-01-30 Curiox Biosystems Pte Ltd. Apparatus and method for multiple reactions in small volumes
KR101918024B1 (ko) * 2010-08-16 2018-11-14 피어이스 파마슈티컬즈 게엠베하 헵시딘 결합 단백질
US8987415B2 (en) 2010-09-07 2015-03-24 Technische Universitaet Muenchen Recombinant bacterial lipocalin blc and uses thereof
AU2011331232B2 (en) 2010-11-15 2015-05-07 Pieris Ag Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
CA2819356C (en) 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
DK2646552T3 (en) 2010-12-02 2017-10-23 Pieris Pharmaceuticals Gmbh MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4
AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
WO2012136685A1 (en) 2011-04-04 2012-10-11 Pieris Ag Methods and compositions for anti-vegf and anti-c-met therapy
JP6317670B2 (ja) 2011-08-15 2018-04-25 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌プロテインａに対する抗体に関連した組成物および方法
CN108144058A (zh) 2011-09-30 2018-06-12 中外制药株式会社 促进抗原消除的抗原结合分子
KR102276528B1 (ko) 2011-09-30 2021-07-12 추가이 세이야쿠 가부시키가이샤 이온 농도 의존성 결합 분자 라이브러리
CN110655578A (zh) 2011-09-30 2020-01-07 中外制药株式会社 诱导针对靶抗原的免疫应答的抗原结合分子
WO2013051294A1 (ja) 2011-10-05 2013-04-11 中外製薬株式会社 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
AU2012325017A1 (en) 2011-10-17 2014-04-17 Westfaelische Wilhelms-Universitaet Muenster Assessment of PML risk and methods based thereon
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
US9610356B2 (en) 2011-12-12 2017-04-04 Pieris Pharmaceutical GmbH Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
CN109432402B (zh) 2011-12-13 2022-04-29 皮里斯制药有限公司 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法
SG11201403887WA (en) 2012-01-09 2014-08-28 Pieris Ag Methods for preventing, treating or diagnosing disorders
US9758554B2 (en) 2012-01-31 2017-09-12 Technische Universitaet Muenchen Muteins of α1m lipocalin and method of production therefor
EP2817625A2 (en) 2012-02-23 2014-12-31 Stage Cell Therapeutics GmbH Chromatographic isolation of cells and other complex biological materials
TW202231872A (zh) 2012-02-24 2022-08-16 日商中外製藥股份有限公司 經FcγRIIB促進抗原消失之抗原結合分子
EP2647995B8 (en) 2012-04-02 2015-02-18 Roche Diagnostics GmbH Methods and use for assessing chronic obstructive pulmonary disease (COPD) severity
CA2910320A1 (en) 2012-04-26 2013-10-31 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
US9683030B2 (en) 2012-05-10 2017-06-20 Massachusetts Institute Of Technology Agents for influenza neutralization
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
US20150353630A1 (en) 2012-05-30 2015-12-10 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
TWI617578B (zh) 2012-05-30 2018-03-11 Chugai Pharmaceutical Co Ltd 標的組織專一的抗原結合分子
WO2013189521A1 (en) 2012-06-19 2013-12-27 Waclawczyk Simon Method of generating cells of hepatocyte phenotype
EP2687850A1 (en) 2012-07-19 2014-01-22 Roche Diagniostics GmbH Methods of stratifying for respiratory support therapy
WO2014025546A2 (en) 2012-08-07 2014-02-13 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
SG11201501382YA (en) 2012-08-27 2015-03-30 Univ Nanyang Tech Nanoparticulate contrast agent
CA2884151A1 (en) 2012-09-10 2014-03-13 Westfaelische Wilhelms-Universitaet Muenster Methods and compounds for preventing, treating and diagnosing an inflammatory condition
EP3456734B1 (en) 2012-10-04 2022-01-05 Research Development Foundation Serine protease molecules and therapies
EP2920202B1 (en) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
US20150316536A1 (en) 2012-12-10 2015-11-05 Fred Hutchinson Cancer Research Center Methods for screening
CN105246503A (zh) 2013-03-14 2016-01-13 第一三共株式会社 Pcsk9的新颖结合蛋白
US9944992B2 (en) 2013-03-15 2018-04-17 The University Of Chicago Methods and compositions related to T-cell activity
WO2014140197A1 (en) 2013-03-15 2014-09-18 Westfaelische Wilhelms-Universitaet Muenster Detection of acute renal allograft rejection
EP3783017A1 (en) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US10526375B2 (en) 2013-06-05 2020-01-07 Massachusetts Institute Of Technology Human Adaptation of H7 HA
EP3013362B1 (en) 2013-06-28 2021-08-04 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
US9557318B2 (en) 2013-07-09 2017-01-31 Curiox Biosystems Pte Ltd. Array plates for washing samples
KR102276745B1 (ko) 2013-07-23 2021-07-14 바이오콘 리미티드 Cd6 결합 파트너의 용도 및 이에 기초한 방법
AU2014306592B2 (en) 2013-08-14 2019-04-04 Bristol-Myers Squibb Company Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US20160289270A1 (en) 2013-11-18 2016-10-06 Westfaelische Wilhelms-Universitaet Muenster Methods, Peptides and Antibodies for Preventing, Treating and Diagnosing an Inflammatory Condition
TWI702316B (zh) 2013-12-04 2020-08-21 日商中外製藥股份有限公司 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
WO2015104406A2 (en) 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
CA2936833A1 (en) 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
CA2938495A1 (en) 2014-02-11 2015-08-20 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
LU92409B1 (en) 2014-03-21 2015-09-22 Philipps Universit T Marburg Means and methods for itaconic acid production
CA3176848A1 (en) 2014-04-16 2015-10-22 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
US11150239B2 (en) 2014-04-30 2021-10-19 Iba Lifesciences Gmbh Method of isolating a target cell
ES2823563T3 (es) 2014-05-22 2021-05-07 Pieris Pharmaceuticals Gmbh Polipéptidos de unión específica novedosos y usos de los mismos
MA41022A (fr) 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
MX2017009767A (es) 2015-01-28 2018-08-15 Pieris Pharmaceuticals Gmbh Nuevas proteínas específicas para la angiogénesis.
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
EP3064507A1 (en) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
JP6884708B2 (ja) * 2015-05-04 2021-06-09 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｃｄ１３７に特異的なタンパク質
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
AU2016262845B2 (en) 2015-05-18 2020-07-23 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
KR20180008649A (ko) * 2015-05-18 2018-01-24 피어이스 파마슈티컬즈 게엠베하 글리피칸-3(gpc3)에 대해 친화도를 갖는 인간 리포칼린 2의 뮤테인
US10545139B2 (en) 2015-06-16 2020-01-28 Curiox Biosystems Pte Ltd. Methods and devices for performing biological assays using magnetic components
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
KR20230079500A (ko) 2015-09-18 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8에 결합하는 항체 및 그의 사용
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
AU2016341527B2 (en) 2015-10-22 2023-04-27 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
KR20180083943A (ko) * 2015-11-30 2018-07-23 피어이스 오스트레일리아 피티와이 엘티디 신규한 항-혈관형성 융합 폴리펩타이드
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2017143026A1 (en) 2016-02-16 2017-08-24 Research Development Foundation Sortase-modified molecules and uses thereof
US10842743B2 (en) 2016-04-08 2020-11-24 The Regents Of The University Of California Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
US20200207846A1 (en) 2016-11-28 2020-07-02 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
AU2017364817B2 (en) 2016-11-28 2023-11-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
BR112019014691A2 (pt) 2017-01-18 2020-04-07 Pieris Pharmaceuticals Gmbh muteínas de lipocalina com afinidade de ligação para lag-3
EP3607580B1 (en) 2017-04-05 2023-05-31 Curiox Biosystems Pte Ltd. Methods, devices, and apparatus for washing samples on array plates
CN111032850A (zh) 2017-04-27 2020-04-17 朱诺治疗学有限公司 寡聚粒子试剂及其使用方法
US20210156844A1 (en) 2017-05-02 2021-05-27 Bayer Aktiengesellschaft TMEM16A Modulation for Diagnostic or Therapeutic Use in Pulmonary Hypertension (PH)
AU2018358804A1 (en) 2017-11-02 2020-04-09 Bayer Aktiengesellschaft Bispecific antibodies binding ALK-1 and BMPR-2
CA3083346A1 (en) 2017-11-28 2019-06-06 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand-binding activity
MX2020005220A (es) 2017-11-28 2020-08-24 Chugai Pharmaceutical Co Ltd Polipeptido que incluye dominio de union al antigeno y seccion de transporte.
WO2019244973A1 (ja) 2018-06-20 2019-12-26 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
WO2019243564A1 (en) 2018-06-21 2019-12-26 Technische Universitaet Muenchen Hepatitis b and/or hepatitis d-permissive cells and animals
PE20210343A1 (es) 2018-08-10 2021-02-23 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso
WO2020043693A1 (en) 2018-08-29 2020-03-05 Westfälische Wilhelms-Universität Münster Diagnosis of multiple sclerosis
DE102018124022A1 (de) 2018-09-28 2020-04-02 Rheinisch-Westfälische Technische Hochschule (Rwth) Aachen Hyaluronsäurestabilisator
CN113227358A (zh) 2018-10-31 2021-08-06 朱诺治疗学有限公司 选择并刺激细胞的方法及用于所述方法的设备
US20220118089A1 (en) 2019-02-25 2022-04-21 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
EP3943108A4 (en) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN
AU2020253034A1 (en) 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
EP3946415A1 (en) 2019-03-29 2022-02-09 Astrazeneca AB Lipocalin mutein for treatment of asthma
CN113661238A (zh) 2019-04-02 2021-11-16 中外制药株式会社 引入靶特异性外源基因的方法
US20220305135A1 (en) 2019-06-03 2022-09-29 The University Of Chicago Methods and compositions for treating cancer with cancer-targeted adjuvants
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha PROTEAS SUBSTRATE AND POLYPEPTIDE WITH PROTEAS CLEAVAGE SEQUENCE
JPWO2020246563A1 (pt) 2019-06-05 2020-12-10
EP3982369A4 (en) 2019-06-07 2023-06-14 Chugai Seiyaku Kabushiki Kaisha INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING PROCESS, PROGRAM AND METHOD FOR PRODUCTION OF AN ANTIGEN-BINDING MOLECULE OR PROTEIN
EP4045044A1 (en) 2019-10-18 2022-08-24 The Regents Of The University Of California Plxdc activators and their use in the treatment of blood vessel disorders
JP2023500318A (ja) 2019-10-30 2023-01-05 ジュノ セラピューティクス ゲーエムベーハー 細胞選択および／または細胞刺激デバイスならびに使用方法
KR20220097952A (ko) 2019-11-04 2022-07-08 피어이스 파마슈티컬즈 게엠베하 암 치료를 위한 her2/4-1bb 이중특이적 융합 단백질
CN115666594A (zh) 2019-11-29 2023-01-31 苏州诺沃泰医药科技有限公司 Cart细胞在制备治疗癌症的药物中的应用
EP4004545B1 (en) 2020-01-31 2022-11-02 Cell.copedia GmbH Methods of isolating a biological entity
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
TW202220677A (zh) 2020-07-31 2022-06-01 日商中外製藥股份有限公司 含有表現嵌合受體之細胞的醫藥組成物
US20230220589A1 (en) * 2020-09-30 2023-07-13 Encodia, Inc. Polypeptide terminal binders and uses thereof
US20240108766A1 (en) 2021-01-22 2024-04-04 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
CN117355319A (zh) 2021-03-23 2024-01-05 皮里斯制药有限责任公司 用于癌症治疗的her2/4-1bb双特异性融合蛋白
EP4314829A1 (en) 2021-03-30 2024-02-07 Westfälische Wilhelms-Universität Münster Classification of neurological or psychiatric disease manifestations using multi-dimensional cerebrospinal fluid analysis
EP4334341A2 (en) 2021-05-06 2024-03-13 Juno Therapeutics GmbH Methods for stimulating and transducing t cells
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
WO2022244838A1 (ja) 2021-05-19 2022-11-24 中外製薬株式会社 分子のｉｎ ｖｉｖｏ薬物動態を予測する方法
WO2023017115A1 (en) 2021-08-11 2023-02-16 Iba Lifesciences Gmbh Fractionation of cells based on a marker protein
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779221D1 (de) * 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
DE69534318T2 (de) * 1994-05-18 2006-04-20 Nektar Therapeutics, San Carlos Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
AU5132096A (en) * 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (fr) 1996-10-14 1998-04-23 Firm Forsat Ltd. Procede de preparation de dispersions a base de composants chromogenes
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19926068C1 (de) * 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins

Also Published As

Publication number Publication date
EP1430131A2 (en) 2004-06-23
ES2253561T3 (es) 2006-06-01
CA2461571A1 (en) 2003-04-10
JP4396923B2 (ja) 2010-01-13
WO2003029463A2 (en) 2003-04-10
CN1561394A (zh) 2005-01-05
CN1325644C (zh) 2007-07-11
ATE311451T1 (de) 2005-12-15
WO2003029463A3 (en) 2003-11-27
CA2461571C (en) 2011-07-26
US20060088908A1 (en) 2006-04-27
EP1430131B1 (en) 2005-11-30
AU2002337111B2 (en) 2007-06-07
BRPI0212919B1 (pt) 2017-05-30
DE60207740D1 (de) 2006-01-05
JP2005503829A (ja) 2005-02-10
US7252998B2 (en) 2007-08-07
BRPI0212919B8 (pt) 2021-05-25
WO2003029462A1 (en) 2003-04-10
DE60207740T2 (de) 2006-08-10
HK1067145A1 (en) 2005-04-01

Similar Documents

Publication Publication Date Title
BR0212919A (pt) Muteìnas da lipocalina associada à gelatinase de neutrófilos humanos e proteìnas relacionadas
DK0981343T3 (da) Probucolmonoestere til behandling af kardiovaskulær og inflammatorisk sygdom
DK1068241T3 (da) Antistofvarianter og fragmenter deraf
DK1476541T3 (da) Cytokin (zcytor17-ligand)
DK1149905T3 (da) Fremgangsmåder og præparat til polypeptidteknologi
IS5887A (is) Interferón-beta bræðsluprótín og notkun þeirra
DE69718811T2 (de) Verfahren zur schnellen in-situ analyse ausgewählter bestandteile von homogenen festen zusammensetzungen, insbesondere pharmazeutischen zusammensetzungen
CY1111237T1 (el) Χρηση πραμιπεξολης για αντιμετωπιση αμυοτροφικης πλευρικης σκληρυνσης
DK0733109T3 (da) BMP-12, BMP-13 og seneinducerende præparater dermed
NO20054892D0 (no) Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
BR0009942A (pt) Método e disposição para navegação de interseção rolável em uma interface do usuário
BR9910332A (pt) Polipeptìdio, composição, método para purificação de polipeptìdio a partir de uma composição e método para purificação de um anticorpo a partir de uma composição
DK1660528T3 (da) Mutein af tåre-lipocalin
BR9909382A (pt) Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado
YU7797A (sh) Kombinovana terapija za osteoporozu
WO2004042394A3 (en) Method for providing natural therapeutic agents with high therapeutic index
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
BRPI0414157A (pt) polipeptìdeo isolado, ácido nucleico isolado, método para inibir a infecção por vìrus da sìndrome da mancha branca de um crustáceo, e, alimento para um crustáceo
EP1203775A3 (en) Lymphocyte chemoattractant factor and uses thereof
BR0012327A (pt) Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados
NO971508L (no) Analoger av sur fibroblastvekstfaktor med forökt stabilitet og biologisk aktivitet
DE60236109D1 (de) Klasse-ii-cytokinrezeptoren und deren verwendungen
DE60134408D1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
DK1129194T3 (da) Homologt interleukin-1-ZIL1A4

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/09/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 18/09/2022